2016_Head & Neck COURSE BOOK

HER1 or EGFR targeting

Monoclonal Antibodies Cetuximab Panitumumab Zalutumumab

EGF receptor

Tumor cell cytoplasmic membrane

Tyrosine kinase Inhibitors

Gefitinib (EGFR) Erlotinib (EGFR) Lapatinib (EGFR + HER2) Afatinib, dacomitinib ( pan-HER)

Tumor proliferation